Many tumor treatments work by disrupting the forming of new blood vessels that feed developing tumors. Agents that block a vessel-promoting aspect called VEGF show promise in human medical trials. But recent research in mice show that when treatment stops, tumor growth rapidly resumes. Now, Yoshiaki Kubota and co-workers find that blocking a different molecule, called M-CSF, suppressed tumor growth even after treatment was stopped. Related StoriesScientists discover little molecule that can block development of BRCA-deficient cancers cellsOvarian cancer sufferers with a history of oral contraceptive make use of have better outcomesViralytics enters into medical trial collaboration agreement with MSDKubota and his group compared the efficacy of inhibitors against M-CSF and VEGF in mice with a certain kind of bone tumor.All three events resolved before study completion; none led to discontinuation from the analysis. No serious adverse occasions happening in IIV3-SD recipients had been considered to be linked to vaccination by the investigators. A total of 99 participants in the IIV3-HD group and 103 individuals in the IIV3-SD group discontinued the study owing to serious adverse occasions, none considered to be linked to vaccination. Cardiac disorders and attacks were the most frequent types of serious adverse occasions in both groups . Immunogenicity HAI antibody geometric mean titers and seroprotection prices 28 times after vaccination were significantly higher after vaccination with IIV3-HD than with IIV3-SD for all three vaccine strains .